Skip to content

Study · Non-randomized trial · n = 45 · 1997

4 results

Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).

Adamson GD, Heinrichs WL, Henzl MR, Yuzpe AA, Bergquist C, Jacobson JJ, Eriksson S, Kwei L, Gilbert SM

American journal of obstetrics and gynecology1 Dec 1997Cited by 12 (Europe PMC)

PMID9423744 (opens in a new tab)DOI10.1016/s0002-9378(97)70084-x (opens in a new tab)PepBankPUB-09423744
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with recurrent endometriosis, repeat nafarelin treatment significantly alleviated symptoms and signs from baseline.

    In plain wordsRepeat nafarelin treatment reduced recurrent endometriosis symptoms and signs compared with baseline.

    Peptide
    Nafarelin
    Outcome
    DecreaseRecurrent endometriosis symptoms and signs
    Study

    n = 45

    Comparator
    Before repeat treatment
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    400 mcg/day · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Repeated 3-month treatment significantly alleviated recurrent symptoms and signs of endometriosis.
    1 context sentence
    Summary · context
    Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months.
  2. 02HumanNon-randomized trialSafety outcome

    In women retreated with nafarelin, lumbar bone mineral density decreased significantly by a mean of 2% at treatment completion.

    In plain wordsLumbar bone density decreased from baseline with repeat nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseLumbar bone mineral density at treatment completion
    Study

    n = 45

    Comparator
    Before repeat treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 mcg/day · intranasal · 3 monthsAs given in this study (human).

    Measurements

    Mean lumbar bone mineral density decrease
    2%
    end of repeat treatment

    Source sentences

    Summary
    Lumbar bone mineral density decreased significantly by a mean of 2% at the end of treatment; this loss was restored within 3 to 6 months after treatment completion.
    1 context sentence
    Summary · context
    Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months.
  3. 03HumanNon-randomized trialSafety outcome

    In women retreated with nafarelin, lumbar bone mineral density loss was restored within 3 to 6 months after treatment completion.

    In plain wordsLumbar bone density recovered after repeat nafarelin treatment compared with treatment completion.

    Peptide
    Nafarelin
    Outcome
    IncreaseLumbar bone mineral density recovery after treatment
    Study

    n = 45

    Comparator
    End of treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 mcg/day · intranasal · 3 monthsAs given in this study (human).

    Measurements

    Time to restoration
    3 to 6 months
    after treatment completion

    Source sentences

    Summary
    Lumbar bone mineral density decreased significantly by a mean of 2% at the end of treatment; this loss was restored within 3 to 6 months after treatment completion.
    1 context sentence
    Summary · context
    Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months.
  4. 04HumanNon-randomized trialSafety outcome

    In women retreated with nafarelin, distal radius bone mineral density did not decline from baseline.

    In plain wordsRadius bone density did not decline from baseline with repeat nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeDistal radius bone mineral density
    Study

    n = 45

    Comparator
    Before repeat treatment
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 mcg/day · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    No bone mineral density decline occurred in the radius.
    1 context sentence
    Summary · context
    Forty-five women previously treated for 6 months with nafarelin, who had recurrent symptoms and signs of endometriosis, received 400 mcg/day of nafarelin intranasally for 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.